

## DAFTAR PUSTAKA

- Agoro R, Mura C. 2019. Iron supplementation therapy, a friend and foe of mycobacterial infections? *Pharmaceuticals*. 12(2):1–28.
- Amalia H, Tabri F, Vitayani S, Petellongi I. 2017. Hemoglobin and Ferritin Serum Levels on Leprosy Patients before Multi Drug Therapy - World Health Organization (Mdt-Who) Compared with Healthy Control Group. *Int. J. Sci. Basic Appl. Res.* 36(4):74–82.
- Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP, Deshpande S. 2007. Circulating cytokine profiles in leprosy patients. *Lepr. Rev.* 78(3):223–230.
- Bommanavar S, Ingale Y, Ingale M, Ingale S. 2018. Leprosy of the hard palate: A rare case report. *J. Oral Maxillofac. Pathol.* 22(3):121–125.
- Bujawati E, Nildawati, Alam AS. 2016. Gambaran Persepsi Pasien Tentang Penyakit Kusta dan Dukungan Keluarga Pada Pasien Kusta di RS Dr. Tadjuddin Chalid Makassar Tahun 2015. *Al-Sihah Public Heal. Sci. J.* 8(1):29–38.
- Butti AK, Yadav SK, Verma A, Khurana VK, Jain S, Singh S, Sarin N. 2019. Serum Levels of Interleukin-1 $\beta$  and Interferon- $\gamma$  in Hansen's disease. *Ann. Med. Health Sci. Res.* 9:465–468.
- Chaptini C, Marshman G. 2015. Leprosy: a review on elimination, reducing the disease burden, and future research. *Lepr. Rev.* 86(4):307–315.
- Chua E. 2018. Anaemia in the Older Person. *Gerontol. Geriatr. Med.* 4(1):1–11.
- Contreras I, Paredes-Cervantes V, García-Miranda LA, Pliego-Rivero FB, Estrada JA. 2016. Leukocyte production of IFN- $\gamma$  and TNF- $\alpha$  in 8- to 12-y-old children with low serum iron levels. *Nutrition.* 32(5):546–552.
- Cortela DCB, Souza Junior ALD, Virmond MCL, Ignotti E. 2015. Inflammatory mediators of leprosy reactional episodes and dental infections: A systematic review. *Mediators Inflamm.*(548540):1–15.
- Cunha C, Pedrosa VL, Dias LC, Braga A. 2015. A historical overview of leprosy epidemiology and control activities in Amazonas, Brazil. *Rev. Soc. Bras.*

*Med. Trop.* 48(1):55–62.

- Delfina M, Wandita S, Laksanawati IS. 2017. Faktor Risiko Anemia pada Pasien Kusta Anak dalam terapi MDT (Multi Drug Therapy). *Sari PEDIATR.* 18(5):363–367.
- Fischer M. 2017. Leprosy – an overview of clinical features, diagnosis, and treatment. *JDDG - J. Ger. Soc. Dermatology.* 15(8):801–827.
- Fonseca AB de L, Simon M do V, Cazzaniga RA, de Moura TR, de Almeida RP, Duthie MS, Reed SG, de Jesus AR. 2017. The influence of innate and adaptative immune responses on the differential clinical outcomes of leprosy. *Infect. Dis. Poverty.* 6(1):1–8.
- Forrellad MA, Klepp LI, Gioffré A, García JS, Morbidoni HR, de la Paz Santangelo M, Cataldi AA, Bigi F. 2013. Virulence factors of the mycobacterium tuberculosis complex. *Virulence.* 4(1):3–66.
- Gustam TYP, Agusni I, Nuswantoro D. 2017. Hubungan antara Riwayat Kontak dengan Kejadian Kusta Multibasiler. Di dalam: *The 6th University Research Colloquium.* Magelang: Universitas Muhammadiyah Magelang. hlm. 35–40.
- Hess S, Rambukkana A. 2019. Cell Biology of Intracellular Adaptation of Mycobacterium leprae in the Peripheral Nervous System. *Microbiol. Spectr.* 7(4):1–30.
- Van Hooij A, Fat EMTK, Van Den Eeden SJF, Wilson L, Da Silva MB, Salgado CG, Spencer JS, Corstjens PLAM, Geluk A. 2017. Field-friendly serological tests for determination of M. Leprae-specific antibodies. *Sci. Rep.* 7(1):1–8.
- Hooij A van, Tió-Coma M, Verhard EM, Khatun M, Alam K, Tjon Kon Fat E, de Jong D, Sufian Chowdhury A, Corstjens P, Richardus JH, *et al.* 2020. Household Contacts of Leprosy Patients in Endemic Areas Display a Specific Innate Immunity Profile. *Front. Immunol.* 11(1):1–12.
- Jadhav R, Suneetha L, Kamble R, Shinde V, Devi K, Chaduvula MV, Raju R, Suneetha S, Nicholls PG, van Brakel WH, *et al.* 2011. Analysis of antibody and cytokine markers for leprosy nerve damage and reactions in the INFIR cohort in India. *PLoS Negl. Trop. Dis.* 5(3):1–8.
- Jin S-H, Ahn KJ, An S. 2018. Importance of the immune response to Mycobacterium leprae in the skin. *Biomed. Dermatology.* 2(1):1–6.

- Kak G, Raza M, Tiwari BK. 2018. Interferon-gamma (IFN- $\gamma$ ): Exploring its implications in infectious diseases. *Biomol. Concepts*. 9(1):64–79.
- Kernan KF, Carcillo JA. 2017. Hyperferritinemia and inflammation. *Int. Immunol.* 29(9):401–409.
- Koehler K, Braun H, Achtzehn S, Hildebrand U, Predel HG, Mester J, Schänzer W. 2012. Iron status in elite young athletes: Gender-dependent influences of diet and exercise. *Eur. J. Appl. Physiol.* 112(2):513–523.
- Kumar B, Kar HK. 2017. *IAL Textbook of Leprosy*. 2nd Ed. New Delhi: Jaypee.
- Lapinsky SE, Baynes RD, Schulz EJ, Macphail AP, Mendelow B, Lewis D, Bothwell TH. 1992. Anaemia, iron-related measurements and erythropoietin levels in untreated patients with active leprosy. *J. Intern. Med.* 232(1):273–278.
- Lastória JC, de Abreu MAMM. 2014a. Leprosy: A review of laboratory and therapeutic aspects - Part 2. *An. Bras. Dermatol.* 89(3):389–401.
- Lastória JC, de Abreu MAMM. 2014b. Leprosy: Review of the epidemiological, clinical, and etiopathogenic aspects - Part 1. *An. Bras. Dermatol.* 89(2):205–218.
- Ma Y, Pei Q, Zhang L, Lu J, Shui T, Chen J, Shi C, Yang J, Smith M, Liu Y, *et al.* 2018. Live mycobacterium leprae inhibits autophagy and apoptosis of infected macrophages and prevents engulfment of host cell by phagocytes. *Am. J. Transl. Res.* 10(9):2929–2939.
- Malathi M, Thappa DM. 2013. Fixed-duration therapy in leprosy: Limitations and opportunities. *Indian J. Dermatol.* 58(2):93–100.
- Mallongi A, Handayani, Selomo M, Daud A, Stang Abdul Rahman, Mattangang A, Muhith A. 2018. The Spatial Pattern and Risk Factors of Leprosy Occurrence in Barru, Indonesia. *Indian J. Public Heal. Res. Dev.* 9(8):1489–1499.
- Manandhar R, LeMaster JW, Butlin CR, Brennan PJ, Roche PW. 2000. Interferon-gamma responses to candidate leprosy skin-test reagents detect exposure to leprosy in an endemic population. *Int. J. Lepr. Other Mycobact. Dis.* 68(1):40–48.
- Mayangsari R, Zulkarnain I, Setyaningrum T. 2016. Profil Interferon- $\gamma$  dan Skar BCG sebagai Gambaran Respons Imun pada Pasien Kusta Anak. *Berk. Ilmu*

*Kesehat. Kulit dan Kelamin.* 28(3):1–8.

McCormick CD, Lea J, Stryjewska BM, Thompson A, Fairley JK. 2019. Trends of leprosy and multibacillary infection in the state of Georgia since the early 1900s. *PLoS Negl. Trop. Dis.* 13(10):1–10.

Moraes MO, Sarno EN, Almeida AS, Saraiva BCC, Nery JAC, Martins RCL, Sampaio EP. 1999. Cytokine mRNA expression in leprosy: A possible role for interferon- $\gamma$  and interleukin-12 in reactions (RR and ENL). *Scand. J. Immunol.* 50(5):541–549.

Moubasher AEDA, Kamel NA, Zedan H, Raheem DEDA. 1998. Cytokines in leprosy, I. Serum cytokine profile in leprosy. *Int. J. Dermatol.* 37(10):733–740.

Muhaira WT, Darmi M, Lubis RD. 2018. Hemolytic anemia incident in leprosy patients receiving multi-drug therapy at Haji Adam Malik Central Hospital, Medan-Indonesia. *Bali Med. J.* 7(2):442–446.

Mukhopadhyay S, Nair S, Ghosh S. 2012. Pathogenesis in tuberculosis: Transcriptomic approaches to unraveling virulence mechanisms and finding new drug targets. *FEMS Microbiol. Rev.* 36(2):463–485.

Nada E, Taieb M El, Fayed H, Ibrahim H, Yasin Y. 2018. Serum interleukin-6 and interferon- $\gamma$  in patients with leprosy. *Egypt. J. Dermatology Venereol.* 38(2):80–84.

Narang T, Kumar B. 2019. Leprosy in Children. *Indian J. Paediatr. Dermatology.* 20(1):12–24.

Nery JS, Ramond A, Pescarini JM, Alves A, Strina A, Ichihara MY, Fernandes Penna ML, Smeeth L, Rodrigues LC, Barreto ML, *et al.* 2019. Socioeconomic determinants of leprosy new case detection in the 100 Million Brazilian Cohort: a population-based linkage study. *Lancet Glob. Heal.* 7(9):e1226–e1236.

Pandey R, Rodriguez GM. 2012. A ferritin mutant of Mycobacterium tuberculosis is highly susceptible to killing by antibiotics and is unable to establish a chronic infection in mice. *Infect. Immun.* 80(10):3650–3659.

Penna GO, Bühner-Sékula S, Kerr LRS, Stefani MM de A, Rodrigues LC, de Araújo MG, Ramos AMC, de Andrade ARC, Costa MB, Rosa PS, *et al.*

2017. Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients. *PLoS Negl. Trop. Dis.* 11(7):1–19.
- Pinheiro RO, Schmitz V, de Andrade Silva BJ, Dias AA, de Souza BJ, de Mattos Barbosa MG, de Almeida Esquenazi D, Pessolani MCV, Sarno EN. 2018. Innate immune responses in leprosy. *Front. Immunol.* 9(518):1–15.
- Resende M, Cardoso MS, Ribeiro AR, Flórido M, Borges M, Castro AG, Alves NL, Cooper AM, Appelberg R. 2017. Innate IFN- $\gamma$ -Producing Cells Developing in the Absence of IL-2 Receptor Common  $\gamma$ -Chain. *J. Immunol.* 199(4):1429–1439.
- Romero-Montoya M, Beltran-Alzate JC, Cardona-Castro N. 2017. Evaluation and Monitoring of Mycobacterium leprae Transmission in Household Contacts of Patients with Hansen's Disease in Colombia. *PLoS Negl. Trop. Dis.* 11(1):1–11.
- Saha K, Rao KN, Kashyap A, Sehgal VN, Agrawal SK. 1989. Serum ferritin in lepra reactions. *Int. J. Lepr.* 57(4):867–870.
- Sampaio EP, Moreira AL, Kaplan G, Alvim MFS, Duppre NC, Miranda CF, Sarno EN. 1991. Mycobacterium leprae-Induced Interferon- $\gamma$  Production by Household Contacts of Leprosy Patients: Association with the Development of Active Disease. *J. Infect. Dis.* 164(5):990–993.
- Santos MB, Dos Santos AD, Barreto AS, Souza MDR, Goes MADO, Barreto Alves JA, Barreto IDC, Silva JRS, De Oliveira DT, De Araújo KCGM, *et al.* 2019. Clinical and epidemiological indicators and spatial analysis of leprosy cases in patients under 15 years old in an endemic area of Northeast Brazil: An ecological and time series study. *BMJ Open.* 9(7):1–9.
- Sembiring K, Lubis B, Rosdiana N, Nafianti S, Siregar OR. 2018. Status Imunitas Anak dengan Anemia Defisiensi Besi. *Cermin Dunia Kedokt.* 45(9):653–655.
- Sengupta U. 2019. Recent Laboratory Advances in Diagnostics and Monitoring Response to Treatment in Leprosy. *Indian Dermatol. Online J.* 10(4):106–114.
- Silva AR da, Neto PML, dos Santos LH, Lima RJCP, Tauil PL, Gonçalves E da G do R. 2018. Factors associated with leprosy in a municipality of the pre-

- amazon region, state of Maranhão, Brazil. *Rev. Soc. Bras. Med. Trop.* 51(6):789–794.
- de Souza VNB, Malaspina TS de S, Campanelli AP, Ghidella C, Ura S, Dalpino D, do Nascimento DC, Latini ACP. 2012. Increased hepcidin expression in multibacillary leprosy. *Mem. Inst. Oswaldo Cruz.* 107(SUPPL.1):183–189.
- Srinivas G, Muthuvel T, Lal V, Vaikundanathan K, Schwienhorst-Stich EM, Kasang C. 2019. Risk of disability among adult leprosy cases and determinants of delay in diagnosis in five states of India: A case-control study. *PLoS Negl. Trop. Dis.* 13(6):1–15.
- Sritharan M. 2016. Iron homeostasis in Mycobacterium tuberculosis: Mechanistic insights into siderophore-mediated Iron uptake. *J. Bacteriol.* 198(18):2399–2409.
- Syakam A, Gutlapalli VR, Tenali SP, Meena AK, Chandran P, Pratap DVS, Suneetha S, Suneetha LM. 2015. Association of tumor necrosis factor-alpha and interferon gamma gene polymorphisms and their plasma levels in leprosy, HIV and other peripheral neuropathies. *Cytokine.* 76(2):473–479.
- Tamara R, Muchtar SV, Amin S, Seweng A, Sjahril R, Adam AM. 2018. Serum Iron, Total Iron Binding Capacity and Transferrin Saturation Levels in Leprosy Patients before Multi Drug Therapy - World Health Organization (MDT-WHO) Compared with Healthy Control Group. *Int. J. Med. Rev. Case Reports.* 2(4):105–108.
- Teles RMB, Graeber TG, Krutzik SR, Montoya D, Lee DJ, Komisopoulou E, Kelly-scumpia K, Chun R, Iyer SS, Sarno EN, *et al.* 2013. Type I Interferon Suppresses Type II Interferon–Triggered Human Anti-Mycobacterial Responses. *Science (80- ).* 339(6126):1448–1453.
- Vazquez CMP, Netto RSM, Barbosa KBF, de Moura TR, de Almeida RP, Duthie MS, de Jesus AR. 2014. Micronutrients influencing the immune response in leprosy. *Nutr. Hosp.* 29(1):26–36.
- Worobec SM. 2012. Current approaches and future directions in the treatment of leprosy. *Res. Rep. Trop. Med.* 3:79–91.